Kronos Bio Net Worth
Kronos Bio Net Worth Breakdown | KRON |
Kronos Bio Net Worth Analysis
Kronos Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Kronos Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Kronos Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Kronos Bio's net worth analysis. One common approach is to calculate Kronos Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Kronos Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Kronos Bio's net worth. This approach calculates the present value of Kronos Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Kronos Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Kronos Bio's net worth. This involves comparing Kronos Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Kronos Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if Kronos Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Kronos Bio's net worth research are outlined below:
| Kronos Bio generated a negative expected return over the last 90 days | |
| Kronos Bio has some characteristics of a very speculative penny stock | |
| Kronos Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 6.29 M. Net Loss for the year was (112.67 M) with profit before overhead, payroll, taxes, and interest of 9.86 M. | |
| Kronos Bio currently holds about 267.89 M in cash with (78.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Kronos Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 27.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Kronos Bio to Release Quarterly Earnings on Thursday - Defense World |
Kronos Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Kronos Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kronos Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Kronos Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kronos Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kronos Bio backward and forwards among themselves. Kronos Bio's institutional investor refers to the entity that pools money to purchase Kronos Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 461.3 K | Hpm Partners Llc | 2024-12-31 | 410.8 K | Woodline Partners Lp | 2024-12-31 | 309.6 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 301 K | Gentrust, Llc | 2024-12-31 | 295.2 K | Choate Investment Advisors | 2024-12-31 | 274.8 K | Deltec Asset Management Llc | 2024-12-31 | 200 K | Citadel Advisors Llc | 2024-12-31 | 186.7 K | State Street Corp | 2024-12-31 | 171.2 K | Vida Ventures Advisors, Llc | 2024-12-31 | 2.8 M | Vanguard Group Inc | 2024-12-31 | 1.9 M |
Follow Kronos Bio's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 56.72 M.Market Cap |
|
Project Kronos Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.74) | (0.78) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.81) | (0.77) |
When accessing Kronos Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Kronos Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Kronos Bio's profitability and make more informed investment decisions.
Evaluate Kronos Bio's management efficiency
Kronos Bio has return on total asset (ROA) of (0.2513) % which means that it has lost $0.2513 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5908) %, meaning that it created substantial loss on money invested by shareholders. Kronos Bio's management efficiency ratios could be used to measure how well Kronos Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of March 2025, Return On Tangible Assets is likely to drop to -0.64. In addition to that, Return On Capital Employed is likely to drop to -0.78. At this time, Kronos Bio's Total Assets are very stable compared to the past year. As of the 17th of March 2025, Non Current Assets Total is likely to grow to about 42.7 M, while Net Tangible Assets are likely to drop about 225.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.48 | 2.84 | |
| Tangible Book Value Per Share | 2.48 | 2.84 | |
| Enterprise Value Over EBITDA | (0.27) | (0.29) | |
| Price Book Value Ratio | 0.41 | 0.43 | |
| Enterprise Value Multiple | (0.27) | (0.29) | |
| Price Fair Value | 0.41 | 0.43 | |
| Enterprise Value | 53.1 M | 50.4 M |
The management team at Kronos Bio has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kronos Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kronos Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kronos Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kronos Bio time-series forecasting models is one of many Kronos Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kronos Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Kronos Bio Earnings per Share Projection vs Actual
Kronos Bio Corporate Management
| Christopher Dinsmore | Strategic Advisor | Profile | |
| Stephanie Yao | Exec Communications | Profile | |
| Barbara JD | Strategic Advisor | Profile | |
| Marni Kottle | Sr Relations | Profile | |
| Rocio Hoyos | Senior Management | Profile | |
| Joshua Kazam | CoFounder Director | Profile | |
| Sandra Gardiner | Interim Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share | Quarterly Revenue Growth 1.585 | Return On Assets | Return On Equity |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.